CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Hey, so…. RAM is getting crazy expensive at the moment. Thanks to a memory supply crunch mostly attributed to the “artificial intelligence” boom and a huge ...

Wegovy and Zepbound are certain to be top sellers if the federal drug marketplace is launched. The two medications, and others, are set to be priced very advantageously. Under its terms, those ...

$2,963.49 at Lenovo Use code 'LENCYBERDEAL' Note that you must be logged into your Lenovo account (free to sign up) to see this price. The Legion Pro 7 is Lenovo's highest end 16" gaming laptop, ...

Novo Nordisk said a weight-loss drug candidate helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company. The Danish ...

Millions of people in the world are overweight, and Novo Nordisk hopes to capture a growing share of this lucrative treatment opportunity. A Fool since 2019, and a graduate of Cal State LA with a B.S.

This article is part of Gizmodo Deals, produced separately from the editorial team. We may earn a commission when you buy through links on the site. Reading time 2 minutes You don’t need to spend ...

Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite recent setbacks. Novo Nordisk's Q3/25 results showed slowing growth, lowered ...

We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Novo Nordisk A/S (NYSE:NVO) is one of the top non-AI stocks Redditors are buying. Novo Nordisk A/S ...

Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease (AD). But perhaps the larger story associated with the unsurprising result is the market ...